Beyond Markush - Protecting activity not chemical structure

Innovations in Pharmaceutical Technology

Volumn , Issue 30, 2009, Pages 42-46

  Gardner, Steve ^a   Vinter, Andy ^a  

^a Cresset BioMolecular Discovery Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; ATORVASTATIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; VICRIVIROC;

DRUG ACTIVITY; DRUG INDUSTRY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; LIVER TOXICITY; MEDICAL RESEARCH; MOLECULAR INTERACTION; SHORT SURVEY; X RAY CRYSTALLOGRAPHY;

EID: 70349917841     PISSN: 14717204     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (9)

1. USPTO, Federal Register 72, 154 44,992-45,001
2. USPTO, MPEP 803.2 Markush Claims [R-5] - 800 Restriction in Applications Filed Under 35 USC111; Double Patenting
3. In re Harnisch, 631 F.2d 716, 206 USPQ 300 (CCPA 1980)
4. The Pharmaceutical Market Outlook to 2010, Business Insights
5. Fliri A, Development of Technology for Transforming Analysis of Patent Information, Presentation at The International Conference on Trends for Scientific Information Professionals, Nice, October 2008
6. Cheeseright T, Mackey M, Rose S and Vinter JG, Molecular field extrema as descriptors of biological activity: Definition and validation, J Chem Inf Model 46(2), pp665-676, 2006
7. Rose S and Vinter A, Molecular Field Technology and its Applications in Drug Discovery, Innovations in Pharmaceutical Technology 23: pp14-18, 2007
8. Cheeseright T, The Identification of Bioisosteres as Drug Development Candidates, Innovations in Pharmaceutical Technology 28: pp22-26, 2009
9. Bohacek RS, McMartin C and Guida WC, The art and practice of structure-based drug design: a molecular modeling perspective, Med Res Rev 16(1): pp3-50, 1996 (Pubitemid 26037075)